The landscape just keeps changing. So what's the best immunotherapy option for 2nd-line NSCLC?

Is atezolizumab the option of choice?

In this Medscape article Dr. Jack West argues that atezolizumab is arguably a better option for 2nd-line NSCLC treatment than nivolumab or pembrolizumab. This is based on the fact that it's not limited to the PD-L1-positive subgroup like pembrolizumab, it's advantage over docetaxel in the OAK trial, and it's every 3 week dosing schedule (more convenient that nivolumab's every 2 week schedule.